anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: CID 163285897
Trial phase: Phase 2
ATC code: A10BX16
SMILES: CCC(C)C(NC(=O)C(CC(C)C)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(C)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)C(CCC(N)=O)NC(=O)C(C)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(NC(=O)C(CO)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(N)Cc1ccc(O)cc1)C(C)O)C(C)O)C(C)CC)C(C)CC)C(C)C)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N1CCCC1C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1CCCC1C(=O)N1CCCC1C(=O)N1CCCC1C(=O)NC(CO)C(N)=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 28
Group description: Participants received Tirzepatide by SC injection in three dose escalations starting with 2.5mg for four weeks followed by 7.5mg for four weeks followed by 15mg for four weeks.
Eligibility criteria:
Inclusion Criteria:

Have type 2 diabetes (T2DM) for ≥6 months according to the Criteria for Diagnosing Type 2 Diabetes Mellitus (American Diabetes Association 2017).
Have HbA1c of 7.0% to 10.5%, inclusive, as assessed by the central laboratory.
If on metformin, have been treated with stable doses of metformin for at least 3 months.
Have a body mass index (BMI) between 23 and 45 (Inclusive) kilograms per square meter.

Exclusion Criteria:

Have type 1 diabetes (T1D).
Have used any glucose-lowering medication other than metformin within 3 months prior to study entry or during screening/lead-in period or have used any glucagon-like peptide-1 receptor agonists (GLP-1 RAs) at any time in the past 12 months.
Have had any of the following cardiovascular conditions: acute myocardial infarction (MI), New York Heart Association Class III or Class IV heart failure, or cerebrovascular accident (stroke).
Have acute or chronic hepatitis, signs and symptoms of any other liver disease other than nonalcoholic fatty liver disease (NAFLD), or alanine aminotransferase (ALT) level >2.5 times the upper limit of the reference range, as determined by the central laboratory at study entry; participants with NAFLD are eligible for participation in this trial.
Have had chronic or acute pancreatitis any time prior to study entry.
Have an estimated glomerular filtration rate (eGFR) <45 milliliters/minute/1.73 square meter, calculated by the Chronic Kidney Disease-Epidemiology (CKD-EPI) equation.
Have serum calcitonin ≥20 picograms per milliliter, as determined by the central laboratory at study entry.
Have any condition that is a contraindication for use of the GLP-1 RA class (per country-specific labels) at study entry or develop such condition between study entry and randomization.
Intervention: Sotagliflozin
Trial phase: Phase 3
ATC code: A10BK06
SMILES: CCOc1ccc(Cc2cc([C@@H]3O[C@H](SC)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 5291
Group description: Sotagliflozin 200 mg tablet once daily, with possible up-titration in the first 6 months to 400 mg, for up to 28.9 months.
Eligibility criteria:
Inclusion criteria :

Type 2 Diabetes Mellitus with glycosylated hemoglobin (HbA1c) ≥7%.
Estimated glomerular filtration rate (eGFR) ≥25 and ≤60 milliliter/minute (mL/min)/1.73 square meter (m^2).
Age 18 years or older with at least one major cardiovascular risk factor or age 55 years or older with at least two minor cardiovascular risk factors.
Signed written informed consent.

Exclusion criteria:

Antihyperglycemic treatment has not been stable within 12 weeks prior to screening.
Planned coronary procedure or surgery after randomization.
Lower extremity complications (such as skin ulcer, infection, osteomyelitis, and gangrene) identified during screening and requiring treatment at randomization.
Planning to start a sodium-glucose linked transporter-2 (SGLT2) inhibitor during the study.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Intervention: SODIUM CHLORIDE
Trial phase: Phase 3
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 172
Group description: Participants who ingest bowel cleanser on the day of colonoscopy. Participant will ingest the 4L PEG on the day of colonoscopy.

Polyethylene Glycol (PEG): Different method for bowel cleansing using same bowel cleanser.

Same-day dose group : 4L PEG will be ingested on the day of colonoscopy Spli-dose group : 2L PEG will be ingested 1 day before colonoscopy, remaining 2L PEG will be ingested on the day of colonoscopy
Eligibility criteria:
Inclusion Criteria:

all subjects who undergo colonoscopy for various reasons.

Exclusion Criteria:

hemodynamic instability
ileus or bowel obstruction
active inflammatory bowel disease
advanced colon cancer
Intervention: SODIUM CHLORIDE
Trial phase: Phase 3
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 167
Group description: Participants who ingest bowel cleanser by split dose. 2L PEG will be ingested 1 day before colonoscopy. Remaining 2L bowel cleanser will be ingested on the day of colonoscopy.

Polyethylene Glycol (PEG): Different method for bowel cleansing using same bowel cleanser.

Same-day dose group : 4L PEG will be ingested on the day of colonoscopy Spli-dose group : 2L PEG will be ingested 1 day before colonoscopy, remaining 2L PEG will be ingested on the day of colonoscopy
Eligibility criteria:
Inclusion Criteria:

all subjects who undergo colonoscopy for various reasons.

Exclusion Criteria:

hemodynamic instability
ileus or bowel obstruction
active inflammatory bowel disease
advanced colon cancer
Intervention: Bupivacaine
Trial phase: Phase 4
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 2
Group description: Patient will receive genicular nerve block with bupivacaine

bupivacaine: Group 1 will receive genicular nerve block using bupivacaine
Eligibility criteria:
Inclusion Criteria:

Participants 40 to 85 years old who are presenting for minimally invasive total knee arthroplasty under spinal anesthesia and are candidates for peripheral nerve blocks.
Minimally invasive is defined as custom modified instrumentation, a quadriceps sparing arthrotomy that does not extend beyond 1cm proximal to the patella and surgical techniques that focus on soft tissue protection.

Exclusion Criteria:

Patient refusal
American Society of Anesthesiologists physical status classification of 4 or higher
Pre-existing neuropathy in the femoral or sciatic distribution
Coagulopathy
Infection at the site
Chronic opioid use (greater than 3 months)
Pregnancy
Medical conditions limiting physical therapy participation
Any other contra-indication to regional anesthesia
Intervention: Ropivacaine
Trial phase: Phase 2 | Phase 3
ATC code: N01BB09
SMILES: CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 23
Group description: Ropivacaine injection. While looking at the Achilles tendon with ultrasound, the orthopaedic physician will inject 4 mL of 0.5% ropivacaine (numbing medicine) around the area of pain. The needle may be directed just under the skin (and above the tendon) and/or deep to the tendon.

Ropivacaine injection: single dose, subcutaneous injection
Eligibility criteria:
For patients with AT

Inclusion Criteria:

- Clinical diagnosis of chronic (>3 months) AT, consisting of pain with pressure at the achilles tendon and report of pain that is aggravated by physical activity

Exclusion Criteria:

History of foot or ankle surgery, bilateral lateral epicondyle tendinopathy
Comorbidity that would be aggravated by placing hand in water (Raynaud's, thoracic outlet syndrome)
Comorbidity (e.g. stroke, neurological disorder) that limits ability to participate in exercise
Comorbidity (e.g. rheumatic disease, fibromyalgia) that contributes to pain with activity
Peripheral neuropathy
Previous adverse response to a local anesthetic injection
Are pregnant
Are a ballroom dancer

For control participants

Inclusion Criteria:

- Sex, Age and BMI-matched to participant with AT

Exclusion Criteria:

No history of tendinopathy
No condition that limited activity in the past 6 months
History of foot or ankle surgery, bilateral lateral epicondyle tendinopathy
Comorbidity that would be aggravated by placing hand in water (Raynaud's, thoracic outlet syndrome)
Comorbidity (e.g. stroke, neurological disorder) that limits ability to participate in exercise
Comorbidity (e.g. rheumatic disease, fibromyalgia) that contributes to pain with activity
Peripheral neuropathy
Are pregnant
Are a ballroom dancer
Intervention: Lansoprazole
Trial phase: Phase 1
ATC code: A02BC03 | A02BC06 | A02BC53 | A02BD02 | A02BD03 | A02BD07 | A02BD09 | A02BD10
SMILES: Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 20
Group description: Dexlansoprazole 30 mg, delayed-release, capsule, orally, administered as single dose on Day 1.
Eligibility criteria:
Inclusion Criteria:

Is a healthy adult man or woman of Chinese descent.
Is aged 18 to 45 years, inclusive, at the time of informed consent and study medication dose.
Weighs at least 50 kilogram (kg) and has a body mass index (BMI) from 19.0 to 26.0 kilogram per square meter (kg/m^2), inclusive at Screening Visit.

Exclusion Criteria:

Has a known hypersensitivity to any component of the formulation of dexlansoprazole or other drug with the same mechanism of action (including lansoprazole, omeprazole, esomeprazole, rabeprazole, ilaprazole, or pantoprazole), or related compounds.
Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 1 year prior to the Screening visit or is unwilling to agree to abstain from alcohol for 48 hours prior to Check-in (Day -1) throughout the confinement and for 48 hours prior to each clinic visit and drugs throughout the study.
Has used nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patch or nicotine gum) within 28 days prior to Check-in (Day -1) or is unwilling to abstain from these products for the duration of the study.
Has poor peripheral venous access.
Has donated blood products (such as plasma), whole blood or had a significant blood loss (450 millimeter [mL]) within 56 days of Day 1.
Intervention: Lansoprazole
Trial phase: Phase 1
ATC code: A02BC03 | A02BC06 | A02BC53 | A02BD02 | A02BD03 | A02BD07 | A02BD09 | A02BD10
SMILES: Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 20
Group description: Dexlansoprazole 60 mg, delayed-release, capsule, orally, administered as single dose on Day 1.
Eligibility criteria:
Inclusion Criteria:

Is a healthy adult man or woman of Chinese descent.
Is aged 18 to 45 years, inclusive, at the time of informed consent and study medication dose.
Weighs at least 50 kilogram (kg) and has a body mass index (BMI) from 19.0 to 26.0 kilogram per square meter (kg/m^2), inclusive at Screening Visit.

Exclusion Criteria:

Has a known hypersensitivity to any component of the formulation of dexlansoprazole or other drug with the same mechanism of action (including lansoprazole, omeprazole, esomeprazole, rabeprazole, ilaprazole, or pantoprazole), or related compounds.
Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 1 year prior to the Screening visit or is unwilling to agree to abstain from alcohol for 48 hours prior to Check-in (Day -1) throughout the confinement and for 48 hours prior to each clinic visit and drugs throughout the study.
Has used nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patch or nicotine gum) within 28 days prior to Check-in (Day -1) or is unwilling to abstain from these products for the duration of the study.
Has poor peripheral venous access.
Has donated blood products (such as plasma), whole blood or had a significant blood loss (450 millimeter [mL]) within 56 days of Day 1.
Intervention: Tranexamic acid
Trial phase: Phase 4
ATC code: B02AA02
SMILES: NC[C@H]1CC[C@H](C(=O)O)CC1
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 9
Group description: Tranexamic Acid (Lysteda) is an antifibrinolytic drug. Tranexamic Acid will be dosed at 1300mg by mouth three times a day at the start of menses and used during the days that bleeding is heaviest (not to exceed 5 days per menstrual cycle).

Tranexamic Acid: Tranexamic Acid was FDA-approved for the treatment of heavy menstrual bleeding in 2009. Tranexamic Acid is a plasminogen-activator inhibitor that blocks fibrinolysis and reduces plasmin activity. A special formulation was designed for the treatment of heavy menstrual bleeding that reduces gastrointestinal side effects, brand name Lysteda which will be prescribed as 1300 mg to be taken three times per day for up to 5 days of the menstrual period.
Eligibility criteria:
Inclusion Criteria:

Premenopausal women ages 25 -50
Monthly menses
Image-confirmed uterine fibroids of at least 1 cm in size, either submucosal or intramural
Seeking treatment for heavy menstrual bleeding following completed clinical evaluation
Self-reported heavy menstrual bleeding for three months or longer
Completed evaluation for heavy menstrual bleeding within one year of study enrollment
Understands the English language for consent and questionnaires
Able and willing to provide informed consent

Exclusion Criteria:

Class 0 fibroids confirmed by hysteroscopy, saline-infused sonogram, or 3D ultrasound
Uterine sounding length ≥ 14 cm
Uterine size ≥ 20 weeks gestational size
Abnormal endometrial biopsy or incomplete clinical testing to rule out malignancy
Needs or is using hormonal contraception, including estrogen-containing medications
Venous thromboembolic history, clotting disorder, or strong family history of venous thromboembolic events
Breast, uterine, or cervical malignancy
Liver disease or liver tumor
Pelvic inflammatory disease, gonorrhea or chlamydia infection during the past three months
Hemoglobin < 8 mg/dL. For women with hemoglobin 8.0 - 12.0 mg/dL, iron supplement is recommended
Serum creatinine ≥ 1.4
Current pregnancy or currently lactating
Intervention: Bivalirudin
Trial phase: Phase 4
ATC code: B01AE06
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)O
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 16
Group description: Patients randomized to this arm will receive anticoagulation with bivalirudin

Bivalirudin: Continuous infusion
Eligibility criteria:
Inclusion Criteria:

Age 1 day to less than 18 years
Cared for in the pediatric intensive care unit or pediatric cardiac intensive care unit
receiving venovenous or venoarterial ECMO

Exclusion Criteria:

Patients with known or suspected heparin induced thrombocytopenia prior to consent
Patients with hepatic failure defined as coagulopathy with elevated transaminases more than three times normal values
Patients with plan to decannulate from ECMO within 48 hours
Known or suspected pregnant women
Previous enrollment in this study
Primary language spoken that is not English or Spanish
Intervention: cis-N-((4-Cyano-2-(trifluoromethyl)phenyl)methyl)-3-((4-methyl-6-(methylamino)-1,3,5-triazin-2-yl)amino)cyclohexanecarboxamide
Trial phase: Phase 1 | Phase 2
SMILES: CNc1nc(C)nc(NC2CCCC(C(=O)NCc3ccc(C#N)cc3C(F)(F)F)C2)n1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: 10mg capsules of GSK2256294 will be administered in a single dose once daily enterally for a duration of 10 days.

GSK2256294: GSK2256294 will be administered in a single dose once daily enteral for a duration of 10 days.
Eligibility criteria:
Inclusion Criteria:

Age > 18
Head CT evidence of subarachnoid hemorrhage
Digital subtraction cerebral angiography or CT angiogram documenting the presence of a cerebral aneurysm.

Exclusion Criteria:

Symptom onset compatible with SAH of > 3 days prior to admission to OHSU
Absence of an indwelling external ventricular drain
Administration of any of the following inducers/inhibitors of CYP3A4: ritonavir, indinavir, nelfinavir, saquinavir, clarithromycin, telithromycin, chloramphenicol, ketoconazole, itraconazole, nefazodone, cobicistat or enzalutamide.
Suspected or confirmed pregnancy
Preexisting severe neurologic deficit or condition
Chronic renal failure requiring dialysis
Severe terminal disease with life expectancy <6 months
Unable to read or understand written or spoken English or Spanish
Refusal of informed consent
Intervention: Mifepristone
Trial phase: Phase 4
ATC code: G03XB01 | G03XB51
SMILES: [H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](c1ccc(N(C)C)cc1)C1=C3CCC(=O)C=C3CC[C@]12[H]
Sex: Female
Age groups: Child | Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 260
Group description: Oral mifepristone 200 mg, followed by misoprostol 800 mcg administered buccally (at 24-48 hours following mifepristone) or vaginally (as soon as 6 hours following mifepristone)

Mifepristone: Patients will receive Mifeprex® (mifepristone) by pharmacy rather than standard care at clinic visit
Eligibility criteria:
Patient Inclusion Criteria:

Women seeking medication abortion through 70 days gestation
Eligible for Mifeprex® at a study clinical site
English or Spanish speaking
Willing and able to participate in the study, including willing to go to the study pharmacy to obtain mifepristone

Patient Exclusion Criteria:

Not pregnant
Not seeking medication abortion
Under the age of 15

Contraindications for medication abortion

All pharmacists providing services at one of the study pharmacies during the study are eligible for the pharmacist survey and interview.
Intervention: Olopatadine
Trial phase: Phase 2
ATC code: R01AC08 | S01GX09
SMILES: CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: Patanol: Six drops in each eye over a 17 day period.
Eligibility criteria:
Inclusion Criteria:

be at least 18 years old
be willing and able to avoid all disallowed medications and contact lenses
must have a pregnancy test if of childbearing potential
must be able to read an eye chart from 10 feet away

Exclusion Criteria:

must not have any allergies to the study medications
must not have any ocular or non ocular condition that investigator feels will interfere with study parameters
must not have used an investigational drug or device in the past 30 days or concurrently enrolled in another investigational trial
Intervention: Pomaglumetad methionil
Trial phase: Phase 1
SMILES: CSCCC(N)C(=O)NC1(C(=O)O)CS(=O)(=O)C2C(C(=O)O)C21
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Subject will take 40mg pomaglumetad methionil (POMA) twice a day for 14 days.

Pomaglumetad methionil: metabotropic glutamate 2/3 receptor (mGlu2/3R) agonist
Eligibility criteria:
Inclusion Criteria:

Capacity to provide informed consent
Currently using a reliable form of birth control

Exclusion Criteria:

Metal implants in body or a history of metal working
Lifetime diagnosis of asthmatic symptoms within the past 3 years or known sensitivity to contrast agents
Lifetime diagnosis of renal failure/disease
Acute neurological, neuroendocrine, or medical disorder including renal insufficiency (CrCl<40 mL/min/1.73m2)
Lifetime diagnosis of hypertension or diabetes or seizure disorder
IQ<70
Acute risk for suicide and/or violence
Pregnant lactating
Current abuse of substances (alcohol, cocaine, stimulants, cannabis, opiates, sedative hypnotics)
Current use or anticipated need for antipsychotics or mood stabilizers (all antipsychotics, also depakote, lithium, lamotrogine, pregabalin or any med with a mechanism of action like gabapentin), probenecid, selective serotonin reuptake inhibitors, tricyclic antidepressants, and monoamine oxidase inhibitors
More than one previous gadolinium scan
Intervention: Pomaglumetad methionil
Trial phase: Phase 1
SMILES: CSCCC(N)C(=O)NC1(C(=O)O)CS(=O)(=O)C2C(C(=O)O)C21
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 2
Group description: Subject will take 120 mg pomaglumetad methionil (POMA) twice a day for 14 days

Pomaglumetad methionil: metabotropic glutamate 2/3 receptor (mGlu2/3R) agonist
Eligibility criteria:
Inclusion Criteria:

Capacity to provide informed consent
Currently using a reliable form of birth control

Exclusion Criteria:

Metal implants in body or a history of metal working
Lifetime diagnosis of asthmatic symptoms within the past 3 years or known sensitivity to contrast agents
Lifetime diagnosis of renal failure/disease
Acute neurological, neuroendocrine, or medical disorder including renal insufficiency (CrCl<40 mL/min/1.73m2)
Lifetime diagnosis of hypertension or diabetes or seizure disorder
IQ<70
Acute risk for suicide and/or violence
Pregnant lactating
Current abuse of substances (alcohol, cocaine, stimulants, cannabis, opiates, sedative hypnotics)
Current use or anticipated need for antipsychotics or mood stabilizers (all antipsychotics, also depakote, lithium, lamotrogine, pregabalin or any med with a mechanism of action like gabapentin), probenecid, selective serotonin reuptake inhibitors, tricyclic antidepressants, and monoamine oxidase inhibitors
More than one previous gadolinium scan
Intervention: Pomaglumetad methionil
Trial phase: Phase 1
SMILES: CSCCC(N)C(=O)NC1(C(=O)O)CS(=O)(=O)C2C(C(=O)O)C21
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Subject will take 160 mg pomaglumetad methionil (POMA) twice a day for 14 days

Pomaglumetad methionil: metabotropic glutamate 2/3 receptor (mGlu2/3R) agonist
Eligibility criteria:
Inclusion Criteria:

Capacity to provide informed consent
Currently using a reliable form of birth control

Exclusion Criteria:

Metal implants in body or a history of metal working
Lifetime diagnosis of asthmatic symptoms within the past 3 years or known sensitivity to contrast agents
Lifetime diagnosis of renal failure/disease
Acute neurological, neuroendocrine, or medical disorder including renal insufficiency (CrCl<40 mL/min/1.73m2)
Lifetime diagnosis of hypertension or diabetes or seizure disorder
IQ<70
Acute risk for suicide and/or violence
Pregnant lactating
Current abuse of substances (alcohol, cocaine, stimulants, cannabis, opiates, sedative hypnotics)
Current use or anticipated need for antipsychotics or mood stabilizers (all antipsychotics, also depakote, lithium, lamotrogine, pregabalin or any med with a mechanism of action like gabapentin), probenecid, selective serotonin reuptake inhibitors, tricyclic antidepressants, and monoamine oxidase inhibitors
More than one previous gadolinium scan